Rebecca Miksad, MD, MPH, MMS

Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Rebecca Miksad is a medical oncologist and health outcomes researcher who is Associate Professor at Boston Medical Center and serves as Chief Medical Officer at Color Health.

Dr. Rebecca Miksad is a mission-driven Physician-Scientist with extensive expertise in cancer and patient-centric health technology, clinical trials and real world evidence research. As Chief Medical Officer at Color Health, she oversees Color’s medical and clinical functions, driving the expansion of cancer screening, diagnostics, care navigation, and survivorship tools for program participants. At Boston Medical Center, Rebecca established the first High Risk Cancer Genetics clinic at Boston Medical Center, Dr. Miksad is an internationally recognized leader in oncology, clinical trials and data science, with over 100 scientific publications.

Dr. Miksad previously founded and led the Strategic Affairs team and Research Unit at Flatiron Health, developing pioneering healthtech products and establishing industry standards for real-world data. Her work has influenced FDA guidances and advanced Health Equity initiatives. She previously directed the Gastrointestinal Cancer program at Beth Israel Deaconess Medical Center and conducted NIH-funded research. Clinically trained as a medical oncologist, Dr. Miksad holds an MD with Honors from Cornell University and an MPH in Clinical Effectiveness from Harvard University. She also completed a post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT).

Rebecca maintains a clinical practice at Boston Medical Center. A nationally recognized clinician and researcher, Rebecca regularly publishes in leading medical journals, serves on national committees and lectures internationally.

Publications

  • Published 4/1/2025

    Schneeweiss S, Miksad R. Bench to Budget: Integrated Evidence Generation for Medications. Clin Pharmacol Ther. 2025 Apr; 117(4):869-871. PMID: 40110751.

    Read at: PubMed

  • Published 1/10/2025

    Miksad RA, Sarkar S. Evaluating Cancer Screening in the Era of Advanced Causal Inference Methods: Innovation, Adherence, and Health Equity Considerations. JCO Clin Cancer Inform. 2025 Jan; 9:e2400214. PMID: 39792989.

    Read at: PubMed

  • Published 11/1/2024

    Miksad RA. Real-World Evidence in Regulatory Decision Making: Time for Evidence Integration. Clin Pharmacol Ther. 2024 Nov; 116(5):1153-1155. PMID: 39404680.

    Read at: PubMed

  • Published 7/1/2024

    Canavan ME, Wang X, Ascha MS, Miksad RA, Showalter TN, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncol. 2024 Jul 01; 10(7):887-895. PMID: 38753341.

    Read at: PubMed

  • Published 6/1/2024

    Miksad RA, Calip GS. Future of Cancer Treatment Guidelines: Integrating Real-World Insights for Equitable Cancer Care. JCO Clin Cancer Inform. 2024 Jun; 8:e2400081. PMID: 38959447.

    Read at: PubMed

Education

  • Cornell University, MD
  • Harvard University, MMS/MMSc
  • Harvard School of Public Health, MPH
  • Harvard University, BA